Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Clinical evidence

AiiM OLE

14 evidence topics · 3 sources

Objective
Location and study date
Registry dates for the extension study
MilestoneRegistry record
First posted“2026-09-08”
Study start (estimated)“2026-09-30”
Primary completion (estimated)“2029-07-31”
Study completion (estimated)“2029-07-31”
Extension study identifiers
ItemRegistry record
Sponsor protocol number“ANX007-GA-03”
EU CT number“2026-527023-96-00”
Acronym“AiiM OLE”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the extension study
ItemRegistry record
Estimated enrollment“605”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: extension study not yet started

The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.